Divis Laboratories Ltd
Divis Laboratories Ltd (DIVISLAB) last reported results for the quarter ended Jun 2026, with sales of ₹3,080 crore and net profit of ₹902 crore. The stock last traded at ₹9,316, a market capitalisation of ₹2,47,303 crore, on a P/E of 83.0. Over the past 52 weeks the stock has ranged between ₹5,648 and ₹10,000. Figures are as of 6 Oct 2026 and are not real time.
Divis Laboratories Ltd share price and key metrics
- Current price
- ₹9,316
- Market cap
- ₹2,47,303 cr
- Stock P/E
- 83.0
- Book value
- ₹631
- ROE
- 16.5%
- ROCE
- 22.0%
- Dividend yield
- 0.33%
- 52w high / low
- 10000/5648
Metrics as of 6 Oct 2026. Not real time.
Track Divis Laboratories Ltd
Cruxal reads every Divis Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Divis Laboratories Ltd growth and returns
- 10 Years
- 11%
- 5 Years
- 9%
- 3 Years
- 11%
- TTM
- 16%
- 10 Years
- 9%
- 5 Years
- 6%
- 3 Years
- 13%
- TTM
- 29%
- 10 Years
- 22%
- 5 Years
- 13%
- 3 Years
- 35%
- 1 Year
- 58%
- 10 Years
- 18%
- 5 Years
- 17%
- 3 Years
- 15%
- Last Year
- 17%
Divis Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹3,080 cr, up 27.8% from ₹2,410 cr a year earlier. Net profit was ₹902 cr, up 65.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,338 | 2,319 | 2,585 | 2,410 | 2,715 | 2,604 | 2,831 | 3,080 |
| Expenses | 1,622 | 1,576 | 1,699 | 1,681 | 1,827 | 1,714 | 1,897 | 1,825 |
| Operating profit | 716 | 743 | 886 | 729 | 888 | 890 | 934 | 1,255 |
| OPM % | 31% | 32% | 34% | 30% | 33% | 34% | 33% | 41% |
| Other income | 106 | 82 | 86 | 119 | 145 | 14 | 155 | 64 |
| Interest | 1 | 0 | 1 | 3 | 8 | 6 | 6 | 6 |
| Depreciation | 99 | 99 | 107 | 112 | 113 | 118 | 120 | 133 |
| Profit before tax | 722 | 726 | 864 | 733 | 912 | 780 | 963 | 1,180 |
| Tax % | 29% | 19% | 23% | 26% | 24% | 25% | 22% | 24% |
| Net profit | 510 | 589 | 662 | 545 | 689 | 583 | 751 | 902 |
| EPS (₹) | 19.21 | 22.19 | 24.94 | 20.53 | 25.95 | 21.96 | 28.29 | 33.98 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Divis Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,064 | 3,891 | 4,946 | 5,394 | 6,969 | 8,960 | 7,768 | 7,845 | 9,360 | 10,560 | 11,230 |
| Operating profit | 1,450 | 1,269 | 1,874 | 1,826 | 2,867 | 3,885 | 2,370 | 2,210 | 2,973 | 3,442 | 3,967 |
| OPM % | 36% | 33% | 38% | 34% | 41% | 43% | 31% | 28% | 32% | 33% | 35% |
| Net profit | 1,060 | 877 | 1,353 | 1,377 | 1,984 | 2,960 | 1,823 | 1,600 | 2,191 | 2,568 | 2,925 |
| EPS (₹) | 39.95 | 33.04 | 50.96 | 51.85 | 74.75 | 111.52 | 68.69 | 60.27 | 82.53 | 96.73 | 110.18 |
TTM is the trailing twelve months to the most recent quarter.
Divis Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
| Reserves | 5,304 | 5,872 | 6,904 | 7,257 | 9,242 | 11,675 | 12,714 | 13,518 | 14,916 | 16,708 |
| Borrowings | 36 | 63 | 106 | 39 | 5 | 4 | 3 | 3 | 4 | 7 |
| Other liabilities | 762 | 797 | 973 | 1,183 | 1,471 | 1,628 | 1,654 | 1,886 | 1,948 | 3,251 |
| Total liabilities | 6,155 | 6,785 | 8,036 | 8,531 | 10,771 | 13,360 | 14,425 | 15,460 | 16,921 | 20,019 |
| Fixed assets | 1,559 | 1,996 | 2,088 | 2,782 | 3,704 | 4,325 | 4,723 | 4,739 | 5,442 | 6,528 |
| CWIP | 444 | 120 | 492 | 920 | 711 | 470 | 212 | 778 | 1,022 | 2,113 |
| Investments | 1,631 | 1,889 | 1,946 | 971 | 0 | 72 | 77 | 82 | 65 | 69 |
| Other assets | 2,521 | 2,780 | 3,511 | 3,858 | 6,356 | 8,493 | 9,413 | 9,861 | 10,392 | 11,309 |
| Total assets | 6,155 | 6,785 | 8,036 | 8,531 | 10,771 | 13,360 | 14,425 | 15,460 | 16,921 | 20,019 |
As reported by the company. Total assets equal total liabilities by construction.
Divis Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1,150 | 776 | 954 | 1,216 | 1,947 | 1,912 | 2,460 | 1,261 | 1,653 | 2,738 |
| Cash from investing | -1,140 | -478 | -685 | -83 | 75 | -2,195 | -2,708 | -269 | -804 | -2,219 |
| Cash from financing | 2 | -314 | -246 | -1,091 | -35 | -532 | -797 | -799 | -799 | -804 |
| Net cash flow | 13 | -17 | 23 | 41 | 1,987 | -816 | -1,045 | 193 | 50 | -285 |
| Free cash flow | 774 | 502 | 221 | 33 | 1,037 | 1,199 | 1,987 | 258 | 215 | 221 |
| CFO / operating profit | 100% | 82% | 77% | 91% | 90% | 66% | 124% | 74% | 83% | 105% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Divis Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 29% | 22% | 29% | 25% | 32% | 35% | 19% | 16% | 20% | 22% |
| Debtor days | 81 | 95 | 86 | 96 | 88 | 99 | 84 | 100 | 106 | 103 |
| Inventory days | 307 | 314 | 347 | 316 | 329 | 341 | 352 | 364 | 311 | 346 |
| Days payable | 104 | 96 | 96 | 100 | 117 | 96 | 89 | 94 | 88 | 106 |
| Cash conversion cycle | 284 | 313 | 336 | 312 | 300 | 344 | 347 | 370 | 330 | 343 |
| Working capital days | 147 | 176 | 169 | 180 | 152 | 177 | 188 | 206 | 192 | 195 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Divis Laboratories Ltd shareholding pattern
Promoters held 51.88% at Jun 2026, broadly unchanged since Jun 2025. FIIs 20.19% and DIIs 19.29%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 51.89% | 51.89% | 51.89% | 51.88% | 51.88% | 51.88% | 51.88% | 51.88% |
| FIIs | 17.25% | 17.98% | 18.01% | 19.74% | 19.39% | 20.08% | 20.29% | 20.19% |
| DIIs | 20.98% | 20.44% | 20.63% | 18.96% | 19.68% | 19.18% | 19.13% | 19.29% |
| Government | 0.09% | 0.09% | 0.09% | 0.09% | 0.09% | 0.09% | 0.09% | 0.09% |
| Public | 9.79% | 9.58% | 9.39% | 9.32% | 8.96% | 8.75% | 8.61% | 8.53% |
| No. of shareholders | 2,78,899 | 2,80,601 | 2,67,755 | 2,59,825 | 2,49,634 | 2,33,844 | 2,28,006 | 2,26,324 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Divis Laboratories Ltd corporate filings
- Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026Company Updatelow impact
- Intimation of closure of Trading Window from 01.10.2026 till 48 hours of declaration of financial results for the quarter and half year ended 30.09.2026.Insider Trading / SASTlow impact
- Divis Laboratories Ltd announces newspaper publication regarding physical share transfer and dematerialisationCompany Updatelow impact
Cruxal's analysis: Divis Laboratories has published a notice in newspapers regarding a special window for…
Read the full analysis - Divi's Laboratories Limited Announces FY 2025-26 Financial Performance and Dividend Approval at 36th AGMAGM/EGMhigh impact
Cruxal's analysis: Divi's Laboratories Limited successfully concluded its 36th Annual General Meeting…
Read the full analysis - Divi's Laboratories Reports Strong Q1 FY27 Financials with 24% Revenue Growth and Strategic Capex ProgressCompany Updatehigh impact
Cruxal's analysis: Divi's Laboratories Limited reported a strong Q1 FY27 performance with consolidated total…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.